Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00256880
Status:
COMPLETED
Last Update Posted:
2017-01-18
First Post:
2005-11-21
Brief Title:
Pazopanib GW786034 In Subjects With Relapsed Or Refractory Multiple Myeloma
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase II Open-Label Study of Pazopanib GW786034 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma The treatment involves daily dosing A patient may continue to receive the treatment as long as they are benefiting from the treatment Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries Physical exams will be performed before each treatment During the treatment phase the patients will undergo regular assessments for safety and clinical response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None